HKD 11.24
(1.81%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 519.26 Million CNY | 55.63% |
2022 | 352.67 Million CNY | 67.17% |
2021 | 210.96 Million CNY | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q2 | 103.49 Million CNY | 0.0% |
2024 Q1 | 103.49 Million CNY | -28.7% |
2023 Q4 | 145.15 Million CNY | 23.11% |
2023 Q3 | 117.9 Million CNY | -8.52% |
2023 FY | 548.86 Million CNY | 55.63% |
2023 Q2 | 128.89 Million CNY | 0.0% |
2023 Q1 | 128.89 Million CNY | 13.98% |
2022 FY | 352.67 Million CNY | 67.17% |
2022 Q4 | 113.08 Million CNY | 0.0% |
2021 FY | 210.96 Million CNY | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
Uni-Bio Science Group Limited | 325.05 Million HKD | -59.749% |
CK Life Sciences Int'l., (Holdings) Inc. | 739.25 Million HKD | 29.759% |